s
MERIL Announces Successful Primary Outcomes of Next-Gen Myval THV Series in Major RCT, Presented at EuroPCR 2024 – Earns Prestigious Late Breaking Trial Status & The LANCET Acceptance
15-05-2024, 12:03
Meril Life Sciences’ LANDMARK trial, highlighting the safety and effectiveness of the Myval Transcatheter Heart Valve Series, stands out as a key late-breaking trial at EuroPCR 2024. The trial involving 768 patients across 31 sites underscores Meril’s dedication to research and patient well-being. VAPI, India, May 15, 2024 /PRNewswire/ — Exciting news from Meril Life Sciences! […] L'articolo MERIL Announces Successful Primary Outcomes of Next-Gen Myval THV Series in Major RCT, Presented at EuroPCR 2024 – Earns Prestigious Late Breaking Trial Status & The LANCET Acceptance proviene da La Ragione.
CONTINUA A LEGGERE
13
0
0
Guarda anche
La Ragione
10:43
Ancora bombe su Beirut, raid di Israele a Gaza
La Ragione
10:42
Cosa c’è oltre il Big Bang
La Ragione
10:29
Mo: un anno dal 7/10, chiusi 23 dei 38 ospedali di Gaza
La Ragione
10:09